The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America
Open accessAbstract
BACKGROUND: The T-20 vs. Optimized Regimen Only Study 1 (TORO 1) was a randomized, open-label, phase 3 study of enfuvirtide (T-20), a human immunodeficiency virus type 1 (HIV-1) fusion inhibitor. METHODS: Patients from 48 sites in the United States, Canada, Mexico, and Brazil with at least six months of previous treatment with agents in three classes of antiretroviral drugs, resistance to drugs in these classes, or both, and with at least 5000 copies of HIV-1 RNA per milliliter of plasma were randomly assigned in a 2:1 ratio to receive enfuvirtide plus an optimized background regimen of three to five antiretroviral drugs or such a regimen alone (control group). The primary efficacy end point was the change in the plasma HIV-1 RNA level from base line to week 24. RESULTS: A total of 501 patients underwent randomization, and 491 received at least one dose of study drug and had at least one measurement of plasma HIV-1 RNA after treatment began. The two groups were balanced in terms of the median base-line HIV-1 RNA level (5.2 log10 copies per milliliter in both groups), median CD4+ cell count (75.5 cells per cubic millimeter in the enfuvirtide group, and 87.0 cells per cubic millimeter in the control group), demographic characteristics, and previous antiretroviral therapy. At 24 weeks, the least-squares mean change from base line in the viral load (intention-to-treat, last observation carried forward) was a decrease of 1.696 log10 copies per milliliter in the enfuvirtide group, and a decrease of 0.764 log10 copies per milliliter in the control group (P<0.001). The mean increases in CD4+ cell count were 76 cells per cubic millimeter and 32 cells per cubic millimeter, respectively (P<0.001). Reactions at the site of the injections were reported by 98 percent of patients receiving enfuvirtide. There were more cases of pneumonia in the enfuvirtide group than in the control group. CONCLUSIONS: The addition of enfuvirtide to an optimized antiretroviral regimen provided significant antiretroviral and immunologic benefit through 24 weeks in patients who had previously received multiple antiretroviral drugs and had multidrug-resistant HIV-1 infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kilby, J. M., Hopkins, S., Venetta, T. M., DiMassimo, B., Cloud, G. A., Lee, J. Y., Alldredge, L., Hunter, E., Lambert, D., Bolognesi, D., et al. (1998) · Nature Medicine · doi:10.1038/3293 · Cited by 987
Dresser, G. K., Spence, J. D., & Bailey, D. G. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200038010-00003 · Cited by 908
Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
Lazzarin, A., Clotet, B., Cooper, D., Reynes, J., Arastéh, K., Nelson, M., Katlama, C., Stellbrink, H.-J., Delfraissy, J.-F., Lange, J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035211 · Cited by 656
Self-citationA Synthetic Peptide from HIV-1 gp41 Is a Potent Inhibitor of Virus-Mediated Cell—Cell Fusion
Wild, C., Greenwell, T., & Matthews, T. (1993) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1993.9.1051 · Cited by 398
Intent-to-Treat Analysis for Longitudinal Studies with Drop-Outs
Little, R., & Yau, L. (1996) · Biometrics · doi:10.2307/2532847 · Cited by 380
DeGruttola, V., Dix, L., D'Aquila, R., Holder, D., Phillips, A., Ait-Khaled, M., Baxter, J., Clevenbergh, P., Hammer, S., Harrigan, R., et al. (2000) · Antiviral Therapy · doi:10.1177/135965350000500112 · Cited by 326
Kilby, J. M., Lalezari, J. P., Eron, J. J., Carlson, M., Cohen, C., Arduino, R. C., Goodgame, J. C., Gallant, J. E., Volberding, P., Murphy, R. L., et al. (2002) · AIDS Research and Human Retroviruses · doi:10.1089/088922202760072294 · Cited by 198
Self-citationLalezari, J. P., Eron, J. J., Carlson, M., Cohen, C. J., DeJesus, E., Arduino, R. C., Gallant, J. E., Volberding, P. A., Murphy, R. L., Valentine, F. T., et al. (2003) · AIDS · doi:10.1097/00002030-200303280-00007 · Cited by 150
Self-citationRace, E., Dam, E. M., Obry, V., Paulous, S., & Clavel, F. (1999) · AIDS · doi:10.1097/00002030-199910220-00008 · Cited by 131
Vaerenbergh, K. V., Laethem, K. V., Albert, J., Boucher, C. A., Clotet, B., Floridia, M., Gerstoft, J., Hejdeman, B., Nielsen, C. H., Pannecouque, C. C., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.8.2109-2117.2000 · Cited by 94
Cited by
Protein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161
“By binding to gp120/gp41 — the HIV envelope protein responsible for fusion of the virus with host cells — this 36-amino-acid peptide prevents the conformational change in gp41 that is required for viral fusion, and thereby inhibits viral entry into the cel”
BackgroundSynthetic therapeutic peptides: science and market
Vlieghe, P., Lisowski, V., Martinez, J., & Khrestchatisky, M. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2009.10.009 · Cited by 1,476
Approved Antiviral Drugs over the Past 50 Years
De Clercq, E., & Li, G. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-15 · Cited by 1,430
Gazzard, B., & on behalf of the BHIVA Treatment Guidelines Writing Group (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2008.00636.x · Cited by 1,089
Treatment for Adult HIV Infection: 2006 Recommendations of the International AIDS Society–USA Panel
Hammer, S. M., Saag, M. S., Schechter, M., Montaner, J. S. G., Schooley, R. T., Jacobsen, D. M., Thompson, M. A., Carpenter, C. C. J., Fischl, M. A., Gazzard, B. G., et al. (2006) · JAMA · doi:10.1001/jama.296.7.827 · Cited by 1,033
Self-citationAntiviral drugs in current clinical use
De Clercq, E. (2004) · Journal of Clinical Virology · doi:10.1016/j.jcv.2004.02.009 · Cited by 947
HIV-1 Antiretroviral Drug Therapy
Arts, E. J., & Hazuda, D. J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a007161 · Cited by 851
Maraviroc for Previously Treated Patients with R5 HIV-1 Infection
Gulick, R. M., Lalezari, J., Goodrich, J., Clumeck, N., DeJesus, E., Horban, A., Nadler, J., Clotet, B., Karlsson, A., Wohlfeiler, M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0803152 · Cited by 752
Self-citationTreatment for Adult HIV Infection: 2004 Recommendations of the International AIDS Society-USA Panel
Yeni, P. G., Hammer, S. M., Hirsch, M. S., Saag, M. S., Schechter, M., Carpenter, C. C. J., Fischl, M. A., Gatell, J. M., Gazzard, B. G., Jacobsen, D. M., et al. (2004) · JAMA · doi:10.1001/jama.292.2.251 · Cited by 737
Self-citationHIV/AIDS epidemiology, pathogenesis, prevention, and treatment
Simon, V., Ho, D. D., & Abdool Karim, Q. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69157-5 · Cited by 730
Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection
Steigbigel, R. T., Cooper, D. A., Kumar, P. N., Eron, J. E., Schechter, M., Markowitz, M., Loutfy, M. R., Lennox, J. L., Gatell, J. M., Rockstroh, J. K., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708975 · Cited by 691
Self-citationEfficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
Lazzarin, A., Clotet, B., Cooper, D., Reynes, J., Arastéh, K., Nelson, M., Katlama, C., Stellbrink, H.-J., Delfraissy, J.-F., Lange, J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035211 · Cited by 656
Self-citationWilen, C. B., Tilton, J. C., & Doms, R. W. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006866 · Cited by 654
Grinsztejn, B., Nguyen, B.-Y., Katlama, C., Gatell, J. M., Lazzarin, A., Vittecoq, D., Gonzalez, C. J., Chen, J., Harvey, C. M., & Isaacs, R. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60597-2 · Cited by 574
Hirsch, M. S., Brun‐Vezinet, F., Clotet, B., Conway, B., Kuritzkes, D. R., D’Aquila, R. T., Demeter, L. M., Hammer, S. M., Johnson, V. A., Loveday, C., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/375597 · Cited by 514
Self-citationSubgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection
Cooper, D. A., Steigbigel, R. T., Gatell, J. M., Rockstroh, J. K., Katlama, C., Yeni, P., Lazzarin, A., Clotet, B., Kumar, P. N., Eron, J. E., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708978 · Cited by 509
Self-citationEnfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes
Matthews, T., Salgo, M., Greenberg, M., Chung, J., DeMasi, R., & Bolognesi, D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1331 · Cited by 465
Self-citationQuercetin as an Antiviral Agent Inhibits Influenza A Virus (IAV) Entry
Wu, W., Li, R., Li, X., He, J., Jiang, S., Liu, S., & Yang, J. (2015) · Viruses · doi:10.3390/v8010006 · Cited by 425
The Lifetime Cost of Current Human Immunodeficiency Virus Care in the United States
Schackman, B. R., Gebo, K. A., Walensky, R. P., Losina, E., Muccio, T., Sax, P. E., Weinstein, M. C., Seage, G. R., Moore, R. D., & Freedberg, K. A. (2006) · Medical Care · doi:10.1097/01.mlr.0000228021.89490.2a · Cited by 410
Twenty-Six Years of Anti-HIV Drug Discovery: Where Do We Stand and Where Do We Go?
Mehellou, Y., & De Clercq, E. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm900492g · Cited by 368
Hendrix, C. W., Collier, A. C., Lederman, M. M., Schols, D., Pollard, R. B., Brown, S., Jackson, J. B., Coombs, R. W., Glesby, M. J., Flexner, C. W., et al. (2004) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000137371.80695.ef · Cited by 366
Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection
Fätkenheuer, G., Nelson, M., Lazzarin, A., Konourina, I., Hoepelman, A. I. M., Lampiris, H., Hirschel, B., Tebas, P., Raffi, F., Trottier, B., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0803154 · Cited by 364
Self-citationA small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding
Lin, P.-F., Blair, W., Wang, T., Spicer, T., Guo, Q., Zhou, N., Gong, Y.-F., Wang, H.-G. H., Rose, R., Yamanaka, G., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1832214100 · Cited by 357
Janssen, P. A. J., Lewi, P. J., Arnold, E., Daeyaert, F., de Jonge, M., Heeres, J., Koymans, L., Vinkers, M., Guillemont, J., Pasquier, E., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm040840e · Cited by 347
Westby, M., Lewis, M., Whitcomb, J., Youle, M., Pozniak, A. L., James, I. T., Jenkins, T. M., Perros, M., & van der Ryst, E. (2006) · Journal of Virology · doi:10.1128/jvi.80.10.4909-4920.2006 · Cited by 337
Birch bark research and development
Krasutsky, P. A. (2006) · Natural Product Reports · doi:10.1039/b606816b · Cited by 337
Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells
Liao, H.-K., Gu, Y., Diaz, A., Marlett, J., Takahashi, Y., Li, M., Suzuki, K., Xu, R., Hishida, T., Chang, C.-J., et al. (2015) · Nature Communications · doi:10.1038/ncomms7413 · Cited by 336
Madruga, J. V., Berger, D., McMurchie, M., Suter, F., Banhegyi, D., Ruxrungtham, K., Norris, D., Lefebvre, E., de Béthune, M.-P., Tomaka, F., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61049-6 · Cited by 336
Ledergerber, B. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16589-6 · Cited by 307
Twenty years of therapy for HIV-1 infection
Pomerantz, R. J., & Horn, D. L. (2003) · Nature Medicine · doi:10.1038/nm0703-867 · Cited by 284
The entry of entry inhibitors: A fusion of science and medicine
Moore, J. P., & Doms, R. W. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1932511100 · Cited by 278
Current status and challenges of antiretroviral research and therapy
Esté, J. A., & Cihlar, T. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2009.10.007 · Cited by 277
Jiang, S., Lu, H., Liu, S., Zhao, Q., He, Y., & Debnath, A. K. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.11.4349-4359.2004 · Cited by 264
Resistance to enfuvirtide, the first HIV fusion inhibitor
Greenberg, M. L. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh330 · Cited by 258
Novel Therapies Based on Mechanisms of HIV-1 Cell Entry
Kilby, J. M., & Eron, J. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmra022812 · Cited by 254
Self-citationMelby, T., DeSpirito, M., DeMasi, R., Heilek‐Snyder, G., Greenberg, M. L., & Graham, N. (2006) · The Journal of Infectious Diseases · doi:10.1086/504693 · Cited by 112
Self-citationPeptides for Vaccine Development
Hamley, I. W. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c01238 · Cited by 104
Mirsaliotis, A., Nurkiyanova, K., Lamb, D., Kuo, C.-W. S., & Brighty, D. W. (2007) · Journal of General Virology · doi:10.1099/vir.0.82390-0 · Cited by 8
Metadata
- Authors
- Lalezari, J. P., Henry, K., O'Hearn, M., Montaner, J. S. G., Piliero, P. J., Trottier, B., Walmsley, S., Cohen, C., Kuritzkes, D. R., Eron, J. J., Chung, J., DeMasi, R., Donatacci, L., Drobnes, C., Delehanty, J., & Salgo, M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-05-29
- Volume
- 348
- Issue
- 22
- Pages
- 2175-2185
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2133649749
- Cited by
- 914
- References
- 12
- FWCI
- 57.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.